Abstract
Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, exhibits a 5-year survival rate below 10% and extremely poor clinical prognosis. Over 90% of PDAC patients harbor KRAS gene driver mutations, which promote tumor proliferation, invasion, and immunosuppression of the tumor microenvironment through constitutive activation of downstream RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways. Although the therapeutic potential of targeting KRAS has been recognized for decades, its smooth protein structure and lack of traditional drug-binding pockets led to its long-standing classification as an “undruggable” target, resulting in limited efficacy of early targeted agents. Recent breakthroughs with next-generation KRAS inhibitors have transformed the therapeutic landscape for pancreatic cancer. This review synthesizes evidence from basic research and clinical translation to provide a theoretical foundation and practical guidance for the precision treatment of KRAS-mutant pancreatic cancer.
Cite this article as: Li W, Lin X, Liu P, et al. Emerging therapeutic landscapes for KRAS-mutant pancreatic ductal adenocarcinoma: beyond the “undruggable” paradigm. Turk J Gastroenterol. Published online January 30, 2026. doi: 10.5152/tjg.2026.25595
Most read articles by the same author(s)
- Shuang Liu, Xiangjie Wang, Jing Zhang, Yabin Liu, Binghui Li, LncRNA IGFL2-AS1 as a ceRNA Promotes HCT116 Cell Malignant Proliferation via the miR-433-3p/PAK4 Axis , Turkish Journal of Gastroenterology: Vol. 34 No. 5 (2023): Turkish Journal of Gastroenterology
- Da-Qin Zhan, Xing Chen, Rong Wang, Jing Zhang, Dan Yu Zhao, Shu Jing Zhang, Zhi Feng Wang, Rui Jun Ma, Bo Hou, Diagnostic evaluation of appendiceal orifice inflammation in ulcerative colitis , Turkish Journal of Gastroenterology: Vol. 27 No. 5 (2016): Turkish Journal of Gastroenterology

This work is licensed under a Creative Commons Attribution 4.0 International License.